16 clinical trials found.
-
ACNS1833: A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727 IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
ACNS1833 is a prospective randomized phase 3 study comparing selumetinib to CV in previously untreated LGG not associated with neurofibromatosis or BRAFV600E. This non-inferiority study ...Phase
Interventional
TRIAL ROLE: Sub Investigator
-
AALL1631: International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones
The goal of this trial is to reduce treatmentrelated morbidity and mortality without adversely impacting disease free survival (DFS) in Standard Risk (SR) patients, who ...Phase
Interventional
TRIAL ROLE: Sub Investigator
-
AALL1731: A Phase 3 Trial Investigating Blinatumomab (IND# 117467 NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)
While outcomes in SR B-ALL have improved significantly, this population still accounts for approximately half of the overall burden of relapse among children with ALL ...Phase
Interventional
TRIAL ROLE: Sub Investigator
-
Open-label Multicenter Phase 2 Study Evaluating the Efficacy & Safety of Daratumumab in Pediatric & Young Adult Subjects =1 & =30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
If you have been diagnosed with with Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, you may be qualified for this ...Phase
Interventional
TRIAL ROLE: Sub Investigator
-
A PHASE 1 STUDY OF PALBOCICLIB (IND#141416) A CDK 4/6 INHIBITOR IN COMBINATION WITH CHEMOTHERAPY IN CHILDREN WITH RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) OR LYMPHOBLASTIC LYMPHOMA (LL)
This study is evaluating safety and feasibility of palbociclib in combination with an established re-induction platform for children, adolescents and young adults with relapsed/refractory ...Phase
Interventional
TRIAL ROLE: Sub Investigator
-
ACNS1721: A Phase 2 Study of Veliparib (ABT-888 IND # 139199) and Local Irradiation Followed by Maintenance Veliparib and Temozolomide in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600E Mutations
You are being asked to take part in this research study because you have been diagnosed with a type of cancer called high-grade glioma (HGG ...Phase
Interventional
TRIAL ROLE: Sub Investigator
-
APEC1621J: NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE)-PHASE 2 SUBPROTOCOL OF BVD-523FB (ULIXERTINIB) IN PATIENTS WITH TUMORS HARBORING ACTIVATING MAPK PATHWAY MUTATIONS
This is a phase 2 trial of BVD-523FB (ulixertinib) in children with recurrent or refractory solid tumors, CNS tumors, non-Hodgkin lymphomas and histiocytic disorders harboring ...Phase
Interventional
TRIAL ROLE: Sub Investigator
-
ONC201 in Newly Diagnosed Diffuse Intrinsic Pontine Glioma and Recurrent/Refractory Pediatric H3 K27M Gliomas
If you or your child has been diagnosed with high grade gliomas (a type of brain cancer), you or your child may qualify to participate ...Phase
Interventional
TRIAL ROLE: Sub Investigator
-
NMTRC14: NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)
If you or your child have been diagnosed with neuroblastoma that is now in remission, you or your child may be qualified to participate in ...Phase
TRIAL ROLE: Sub Investigator
-
APEC1621SC: NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE) SCREENING PROTOCOL
If you or your child have cancer that has become worse following treatment, or because no standard therapy exists for your type of cancer, you ...Phase
TRIAL ROLE: Sub Investigator
